Valvular & structural heart diseaseCohort study
3-Year Outcomes of Mitral Valve-in-Valve Therapy Using Balloon-Expandable Transcatheter Valves in the United States
- Registry-based cohort study
- TVT Registry
- CMS data linkage
Authors' conclusion
Three-year survival after MViV is highest in low STS scores and elective procedures, whereas survival was significantly lower in high STS scores and nonelective procedures.
Study context
- Population
- Patients undergoing transseptal mitral valve-in-valve (MViV) with SAPIEN 3 valve family for failed surgical bioprostheses, TVT Registry, June 2015 to March 2024median follow-up 377 days
- Participants
- 5,971 patients
- Exposure
- Outcomes by Society of Thoracic Surgeons (STS) score and procedure status after transseptal MViV
- Low STSn = 1,310reference
- Intermediate STSn = 1,960
- High STSn = 2,315
- Outcome
- All-cause mortality, stroke and reintervention
- Follow-up
- 3 years
Main finding
As reported in the abstract
All-cause mortality
- Mortality greatest in high STS score and nonelective procedures, lowest in low STS score and elective procedures
Observational data: associations, not effects.
Further findings
Stroke · 3 years
- Stroke rates comparable except between low and high STS groups
Mitral valve reintervention · 3 years
- Reintervention uncommon in all groups
Original publication
3-Year Outcomes of Mitral Valve-in-Valve Therapy Using Balloon-Expandable Transcatheter Valves in the United States. JACC Cardiovasc Interv. Published 9 June 2025. doi:10.1016/j.jcin.2025.03.017
Summarised from the published abstract; every number is checked against it